Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy

This study has suspended participant recruitment.
(Study activities have been suspended while sponsor evaluates nonclinical (rat) findings.The potential relevance of these findings to humans, if any, is unknown.)
Sponsor:
Information provided by (Responsible Party):
Shire
ClinicalTrials.gov Identifier:
NCT01604941
First received: May 22, 2012
Last updated: April 8, 2014
Last verified: April 2014
  Purpose

The purpose of this study is to evaluate SSP-004184AQ in patients with transfusional iron overload whose primary diagnosis is hereditary or congenital anemia.

SSP-004184AQ is an iron chelator under development for chronic daily oral administration to patients with transfusional iron overload.


Condition Intervention Phase
Iron Overload Due to Repeated Red Blood Cell Transfusions
Drug: SPD602
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2, 24 Week, Open Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SSP-004184 (SPD602) in the Treatment of Chronic Iron Overload Requiring Chelation Therapy

Resource links provided by NLM:


Further study details as provided by Shire:

Primary Outcome Measures:
  • Pharmacokinetic parameters of SSP-004184AQ following an 4-16 week period of exposure to capsule dose of SSP-004184AQ at 50 mg/kg total daily dose administered as BID. [ Time Frame: 4-16 week period of expsosure ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Liver iron concentration change as determined by R2 magnetic resonance imaging (MRI) After 12 and 24 Weeks Treatment With SSP-004184AQ at 50 mg/kg total daily dose administered as BID. [ Time Frame: 12 and 24 weeks ] [ Designated as safety issue: Yes ]
  • Safety and tolerability of a SSP-004184AQ dose based on clinical assessments (eg, incidence and severity of TEAEs, physical examinations including vital signs, clinical laboratory values, LVEF and ECGs). [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 50
Study Start Date: September 2012
Estimated Study Completion Date: August 2014
Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SPD602
50 mg/kg/day orally twice daily for 24 weeks
Drug: SPD602
50 mg/kg/day orally twice daily for 24 weeks
Other Name: SSP-004184, deferitazole

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Willing and able to sign the approved informed consent.
  • Age: 18-60 years old, inclusive, at Screening.
  • Subjects who have received more than 20 transfusions in their lifetime and who have transfusional iron overload requiring chronic treatment with an iron chelator. N.B.: Sickle Cell Disease subjects receiving regular exchange transfusions and iron overloaded subjects with thalassemia intermedia who are receiving regular transfusions (transfusion dependent thalassemia intermedia) are eligible.
  • Willing to discontinue all existing iron chelation therapies for a minimum period of one to five days prior to first dose of SSP-004184AQ, the 24 week duration of the study and 1 week after last dose for a total of approximately 26 weeks.
  • Willing to fast two hours prior to and one hour after each dose.
  • Serum ferritin >500ng/mL at Screening.
  • Baseline liver iron concentration is greater than or equal to 5mg iron per g (equivalent dry weight, liver)determined by FerriScan® R2 MRI.
  • Mean of the previous three pre-transfusion hemoglobin concentrations is greater than or equal to 7.5g/dL.
  • Adult female subjects should be:

    1. Post-menopausal (12 consecutive months of spontaneous amenorrhea), or
    2. Surgically sterile, or
    3. Females of child-bearing potential must have a negative beta-HCG pregnancy test at the Screening Visit and a negative urine pregnancy test at the Baseline Visit.

Females of child-bearing potential must agree to abstain from sexual activity that could result in pregnancy or agree to use acceptable methods of contraception.

Exclusion Criteria:

  • As a result of medical review, physical examination, or Screening investigations, the Principal Investigator (PI) considers the subject unfit for the study.
  • Non-elective hospitalization within the 30 days prior to Baseline testing.
  • Evidence of clinically relevant oral, cardiovascular, gastrointestinal, hepatic, biliary, renal, endocrine, pulmonary, neurologic, psychiatric, immunologic, bone marrow, or skin disorder that contraindicates dosing with SSP-004184AQ.
  • Iron overload from causes other than transfusional siderosis.
  • Evidence of severe renal insufficiency, eg, serum creatinine 1.5X above the upper limit of normal or proteinuria greater than 1 gm per day or a calculated glomerular filtration rate <60mL/min.
  • Severe iron overload including:

    1. T2* MRI <10 ms
    2. liver iron concentration by FerriScan R2 MRI >30mg/g liver (dw)
  • Known sensitivity to magnesium stearate, croscarmellose sodium or SSP-004184AQ.
  • Platelet count below 100,000/μL or absolute neutrophil count less than 1500/mm3 at Screening.
  • Insufficient venous access that precludes prescribed blood draws for safety laboratory assessments.
  • ALT at Screening >200 IU/L.
  • Use of any investigational agent within the 30 days prior to the Baseline testing.
  • Pregnant or lactating females.
  • Cardiac left ventricular ejection fraction

    1. Below the locally determined normal range in the 12 months prior to Screening by echocardiograph or MRI or
    2. <50% at Baseline testing by MRI (echocardiograph is acceptable for LVEF if MRI information is not available).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01604941

Locations
United States, California
Children's Center for Cancer and Blood Diseases
Los Angeles, California, United States, 90027
United States, Illinois
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611
United States, New York
Weill Cornell Medical College
New York, New York, United States, 10065
United States, Pennsylvania
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Canada, Ontario
Toronto General Hospital
Toronto, Ontario, Canada, M5G 2C4
Egypt
Ain Shams University Pediatric Hospitals
Cairo, Egypt
Cairo University Pediatric Hospitals
Cairo, Egypt
Italy
Centro della Microcitemia e delle Anemie Congenite
Genova, Genoa, Italy, 16128
Ospedale Regionale Microcitemie
Cagliari, Italy, 09121
Ospedale Maggiore Policlinico
Milan, Italy, 20122
San Luigi Hospital Thalassemia Centre
Orbassano (Torino), Italy, 10043
Lebanon
American University of Beirut Medical Center
Beirut, Lebanon
Sponsors and Collaborators
Shire
Investigators
Principal Investigator: Maria Domenica Cappellini, MD Ospedale Maggiore Policlinico
  More Information

No publications provided

Responsible Party: Shire
ClinicalTrials.gov Identifier: NCT01604941     History of Changes
Other Study ID Numbers: SPD602-203
Study First Received: May 22, 2012
Last Updated: April 8, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Iron Overload
Iron Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on July 31, 2014